Grit Bio（沙砾生物） to Present Next-Gen TIL Therapy Program GT202 at AACR 2022

Grit Bio （沙砾生物） will present GT202, a next-generation (tumor infiltrating therapy) TIL product, which was developed utilizing Grit’s proprietary TIL engineering platform StaViral®, at the American Association for Cancer Research (AACR) Annual Meeting. StaViral® is Grit’s proprietary viral system tailored for TIL engineering. It is a clinically validated viral engineering platform that allows efficient and stable viral transduction in TILs. Based on this platform, Grit has developed multiple next-generation gene-edited TIL pipelines.

The release as fetched from its publisher. gritbio.com ↗